Staging preview: health content pending qualified review
D2C Peptides

Research goal

Ozempic and blood sugar

Ozempic is FDA approved, with diet and exercise, to improve blood sugar control in adults with type 2 diabetes.1 In its label trials, HbA1c fell about 1.2 to 2.1 points from starting levels near 8% to 9%, depending on dose and other medicines.1 This page maps what sources report on Ozempic for type 2 diabetes and makes no promise for any one person.

This page summarizes published sources for information only. It is not medical advice and does not tell anyone to use a product. Questions about your own health belong with a licensed clinician. For questions about an order or a product, contact us.

What sources report

Ozempic for type 2 diabetes rests on the label's blood sugar trials and on two outcome trials in adults with the disease.1 The findings below come from the label and from published trial reports, each named with its size and length.

How Ozempic lowers blood sugar

GLP-1 is a hormone the intestine releases, and it helps lower blood sugar after eating.4 On the label, semaglutide raises insulin release and lowers glucagon release in a glucose-dependent way: when blood sugar is high, insulin release goes up and glucagon release is held back.1 A minor delay in stomach emptying just after meals also plays a part.1 MedlinePlus puts it the same way: semaglutide helps the pancreas release the right amount of insulin when blood sugar is high.3

The risk of low blood sugar depends on what else is taken: in the label's trials, documented symptomatic low blood sugar occurred in up to 3.8% of people on Ozempic alone, but in 29.8% on 1 mg alongside basal insulin.1 Every rate by dose and combination is in Ozempic side effects.

Reaching an HbA1c below 7%

HbA1c is the blood test the label's trials used to judge blood sugar control.1 Besides the average drop, they reported how many people reached an HbA1c below 7%:

  • Ozempic alone, 30 weeks (double-blind, 388 adults, starting near 8.1%): 73% on 0.5 mg and 70% on 1 mg reached below 7%, against 28% on placebo.1
  • 2 mg against 1 mg, 40 weeks (double-blind, 961 adults on metformin with or without a sulfonylurea, starting near 8.8% to 8.9%): 64% on 2 mg and 56% on 1 mg reached below 7%.1
  • The extra step from 1 mg to 2 mg: in SUSTAIN FORTE, the published report of that 40-week trial, people whose HbA1c was still 8% to 10% on metformin, with or without a sulfonylurea, gained an extra 0.18 to 0.23 point drop on 2 mg, depending on the analysis.5

The HbA1c change in each label trial, including a 56-week trial against sitagliptin, is set out in a table in Ozempic benefits and uses.

Compared with tirzepatide (Mounjaro)

SURPASS-2 was an open-label phase 3 trial of 1,879 adults with type 2 diabetes over 40 weeks.6 Tirzepatide 5, 10 and 15 mg lowered HbA1c by 2.01, 2.24 and 2.30 points, against 1.86 for semaglutide 1 mg.6 Stomach and gut effects led in both groups, with nausea in 17% to 22% on tirzepatide and 18% on semaglutide, and serious adverse events occurred in 5% to 7% and 3%.6 Eli Lilly, which makes tirzepatide, funded the trial, and it did not test Ozempic 2 mg.6

The two drugs work differently: Mounjaro acts on two hormone receptors, GIP and GLP-1, while Ozempic acts on GLP-1 alone.71 More on the other drug: Mounjaro and blood sugar and Mounjaro vs Ozempic.

Heart and kidney outcomes in type 2 diabetes

Two of the label's three uses come from outcome trials in adults with type 2 diabetes.1 In SUSTAIN 6 (3,297 adults at high cardiovascular risk), the risk of heart attack, stroke or cardiovascular death was 26% lower on Ozempic.1 In FLOW (3,533 adults with chronic kidney disease), the risk of the main kidney and heart composite was 24% lower on Ozempic 1 mg.1

Eyes when blood sugar falls quickly

The label notes that rapid improvement in blood sugar has been linked to a temporary worsening of diabetic retinopathy, and says people with a history of it should be monitored.1 In SUSTAIN 6, retinopathy complications occurred in 3.0% on Ozempic against 1.8% on placebo, and the gap was larger in people who already had retinopathy (8.2% against 5.2%).1

The Ozempic pill

The once-daily Ozempic tablets share a label with Rybelsus that covers blood sugar control in adults with type 2 diabetes.2 Their first 30 days at 1.5 mg are a starter phase that does not control blood sugar; the label then moves to 4 mg, and to 4 mg or 9 mg from day 61.2

What the label says

  • Use: along with diet and exercise, to improve blood sugar control in adults with type 2 diabetes.1
  • Dose: 0.25 mg once a week for 4 weeks to start, then 0.5 mg; the slow start is meant to lower the risk of stomach and gut side effects.1 If more blood sugar control is needed, the dose may go up to 1 mg and then 2 mg, each after at least 4 weeks on the dose before.1 For the kidney use (type 2 diabetes with chronic kidney disease), the label's maintenance dose is 1 mg.1 The prescriber sets every step.
  • Other diabetes medicines: when Ozempic starts, the label says to consider lowering the dose of insulin or a sulfonylurea to reduce the risk of low blood sugar.1
  • Reduced kidney or liver function: the label recommends no dose adjustment.1
  • Boxed warning: semaglutide causes thyroid C-cell tumors in rodents, and it is unknown whether Ozempic causes them in humans.1 Ozempic must not be used by people with a personal or family history of medullary thyroid carcinoma or with MEN 2.1

The full schedule is in Ozempic dosage, and every listed risk in Ozempic side effects.

The What is Ozempic? profile covers the brand in full. Other compounds people research for this goal are on Peptides and blood sugar. The same molecule in other forms: Semaglutide and blood sugar and Rybelsus and blood sugar.

Read next

More goal pages

Frequently asked questions

What does Ozempic actually do for diabetes?

It lowers blood sugar in adults with type 2 diabetes: semaglutide raises insulin release and lowers glucagon release when blood sugar is high, and it slows stomach emptying.1 In the label's 30-week trial of Ozempic alone, HbA1c fell 1.4 points on 0.5 mg and 1.6 on 1 mg from a start near 8.1%, against 0.1 on placebo.1 In adults with type 2 diabetes and cardiovascular disease or chronic kidney disease, outcome trials also found fewer major cardiovascular events and fewer serious kidney and heart events.1

Is Ozempic a medication for diabetes?

Yes. Ozempic is a prescription medicine for adults with type 2 diabetes: it is approved to improve blood sugar control along with diet and exercise, and to lower heart and kidney risks in some of them.1 FDA first approved the injection in 2017, and the once-daily Ozempic tablets carry a type 2 diabetes label too.12 Weight loss is not an approved use, and the label says safety and effectiveness have not been established in children.1

What is better for diabetics, Wegovy or Ozempic?

They contain the same semaglutide but carry different labels. Ozempic, at up to 2 mg a week, is approved for blood sugar control in adults with type 2 diabetes.1 Wegovy injection, usually 2.4 mg a week, is approved for long-term weight reduction, for lowering heart risk in adults with cardiovascular disease and obesity or overweight, and, under accelerated approval, for the liver disease MASH.8 STEP 2 compared 2.4 mg, 1.0 mg and placebo for 68 weeks in adults with type 2 diabetes and overweight or obesity.9 Average weight fell 9.9% on 2.4 mg against 7.2% on 1.0 mg, and HbA1c fell 1.7 against 1.5 points.10 Which suits a person is the prescriber's decision.

Does Ozempic cause low blood sugar?

It depends on what it is combined with. In the label's trials, documented symptomatic hypoglycemia (glucose at or below 70 mg/dL) occurred in at most 3.8% of people taking Ozempic alone, against 0% on placebo.1 Alongside basal insulin the rate reached 29.8% on 1 mg, and with a sulfonylurea 24.4% on 1 mg.1 The label says the insulin or sulfonylurea dose may need to be lowered when Ozempic starts.1

Written by D2C Peptides Editorial Team.

Pending qualified review.

Updated .

Sources

  1. OZEMPIC (semaglutide) injection, solution: prescribing information, Medication Guide and Instructions for Use (Revised 5/2026, SPL version 20). U.S. National Library of Medicine, DailyMed (label from Novo Nordisk), 2026.
  2. OZEMPIC (oral semaglutide) tablet; RYBELSUS (oral semaglutide) tablet: prescribing information (Revised 1/2026). U.S. National Library of Medicine, DailyMed (label from Novo Nordisk), 2026.
  3. Semaglutide Injection: MedlinePlus Drug Information (last revised 05/15/2026). U.S. National Library of Medicine, MedlinePlus, 2026.
  4. FDA Requests Removal of Suicidal Behavior and Ideation Warning from GLP-1 Receptor Agonist Medications (Drug Safety Communication, 01-13-2026). U.S. Food and Drug Administration, 2026.
  5. Frias JP et al. Efficacy and safety of once-weekly semaglutide 2.0 mg versus 1.0 mg in patients with type 2 diabetes (SUSTAIN FORTE). Lancet Diabetes Endocrinol 2021;9(9):563-574. PubMed (NCBI, NLM), 2021.
  6. Frias JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). N Engl J Med 2021;385(6):503-515. PubMed (NCBI, NLM), 2021.
  7. MOUNJARO (tirzepatide) injection: prescribing information (Revised 8/2026). U.S. National Library of Medicine, DailyMed (label from Eli Lilly and Company), 2026.
  8. WEGOVY (semaglutide) injection and tablets: prescribing information (Revised 6/2026). U.S. National Library of Medicine, DailyMed (label from Novo Nordisk), 2026.
  9. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2). Lancet 2021;397(10278):971-984. PubMed (NCBI, NLM), 2021.
  10. ClinicalTrials.gov NCT03552757: Effect and Safety of Semaglutide 2.4 mg Once-weekly in Subjects With Overweight or Obesity and Type 2 Diabetes (STEP 2), posted results. U.S. National Library of Medicine, ClinicalTrials.gov, 2022.